- Home
- / Nexstim
Nexstim
Stock Price
€5.5
2024-10-29
Market Capitalization
€37.1 M
2024-10-29
Revenue
€11 M
FY, 2025
Nexstim Summary
Company Summary
- Overview
- Nexstim is a company focusing on therapies and diagnostics for brain diseases and disorders. It develops SmartFocus TMS technology, a non-invasive brain stimulation system for the treatment of major depressive disorder.
- Type
- Public
- Status
- Active
- Founded
- 2000
- HQ
- Helsingfors, FI | view all locations
- Website
- https://www.nexstim.com/
- Cybersecurity rating
Table of Contents
Key People
Joonas Juokslahti, CFO
Gustaf Järnefelt, Vice President, R&D
Hanna Kotola, Vice President, Legal Affairs
LocationsView all
4 locations detected
Helsingfors HQ
Finland
Elimägatan 9b
Madison, WI
United States
2921 Landmark Pl #300
Frankfurt am Main, HE
Germany
Lyoner Str. 14
İstanbul
Turkey
Süleymaniye
Nexstim Financials
Summary Financials
- Revenue (FY, 2025)
- €11.0M
- Gross profit (FY, 2025)
- €8.5M
- Net income (FY, 2025)
- €573.0K
- Cash (FY, 2025)
- €2.7M
- EBIT (FY, 2025)
- €693.0K
- Enterprise value
- $38.5M